| TOP PICK | 18.600 | Chris Fernyc | Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet. | 2005-04-14 | |
| TOP PICK | 20.980 | Fred Pynn | A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America. | 2004-11-24 | |
| TOP PICK | 19.500 | Danny Tomka | Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product. | 2004-11-09 | |
| BUY | 17.400 | Peter Arender, CFA | Has a very good ROE. Efficient balance sheet structure. Continuing to grow their earnings. Valuation is reasonable. | 2003-11-11 | |
| TOP PICK | 47.230 | John Sinkins, CFA | The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up. | 2003-11-03 | |
| DON'T BUY | 16.930 | Glenn Paradis, BA, CFA | Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK. | 2003-05-20 | |
| BUY | 17.850 | Pierre Bernard | A good long term hold. They focus on their earnings. Well managed. | 2003-01-20 | |
| DON'T BUY | 21.500 | Malvin Spooner | Had a nice run. May be a bit high now. | 2002-01-31 | |
| STRONG BUY | 14.950 | Ed Ho | Products selling very well. Sales force based in US | 2000-12-11 | |
Experts that have talked about Axcan Pharmaceuticals
Rss Top Picks Feed